N Fintelman-Rodrigues, CQ Sacramento… - Antimicrobial agents …, 2020 - Am Soc Microbiol
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The …
L Nováková, J Pavlík, L Chrenková, O Martinec… - … of pharmaceutical and …, 2018 - Elsevier
This review is a Part II of the series aiming to provide comprehensive overview of currently used antiviral drugs and to show modern approaches to their analysis. While in the Part I …
U Roy, V Drozd, A Durygin, J Rodriguez, P Barber… - Scientific reports, 2018 - nature.com
Abstract Human Immunodeficiency Virus Type 1 (HIV-1) remains one of the leading causes of death worldwide. Present combination antiretroviral therapy has substantially improved …
Background Neurocognitive impairment is present in 50% of HIV-infected individuals and is often associated with Alzheimer's Disease (AD)-like brain pathologies, including increased …
Objectives: Long-acting nanoformulated antiretroviral therapy (nanoART) with improved pharmacokinetics, biodistribution and limited systemic toxicities will likely improve drug …
TO McDonald, M Giardiello, P Martin… - Advanced …, 2014 - Wiley Online Library
Nanomedicine strategies have produced many commercial products. However, no orally dosed HIV nanomedicines are available clinically to patients. Although nanosuspensions of …
Macrophages serve as vehicles for the carriage and delivery of polymer-coated nanoformulated antiretroviral therapy (nanoART). Although superior to native drug, high …
Long-acting nanoformulated antiretroviral therapy (nanoART) that targets monocyte- macrophages could improve the drug's half-life and protein-binding capacities while …
Long-acting injectable nanoformulated antiretroviral therapy (nanoART) was developed with the explicit goal of improving medicine compliance and for drug targeting of viral tissue …